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Objectives. The Intracoronary Stenting and Antithrombotic
Regimen (ISAR) trial is a randomized comparison of combined
antiplatelet with anticoagulant therapy after coronary Palmaz-
Schatz stent placement. The objective of this study was to compare
early and late clinical and angiographic outcome in a subgroup of
patients with stent placement for acute myocardial infarction.
Background. Stenting has become a treatment option for acute
myocardial infarction, but it is not known which antithrombotic
regimen is more adequate after stent implantation.
Methods. One hundred twenty-three patients with successful
stenting after acute myocardial infarction were randomized to
receive aspirin plus ticlopidine (n 5 61) or intense anticoagulant
therapy (n5 62). Six-month repeat angiography was performed in
101 (86.3%) eligible patients.
Results. During the first 30 days after stenting, patients with
antiplatelet therapy had a significantly lower clinical event rate
(3.3% vs. 21.0%, p 5 0.005) and stent vessel occlusion rate (0% vs.
9.7%, p5 0.03) and a trend to fewer cardiac events (1.6% vs. 9.7%,
p 5 0.12). After 6 months, the survival rate free of recurrent
myocardial infarction was higher in patients with antiplatelet
therapy (100% vs. 90.3%, p 5 0.03), and the rate of stent vessel
occlusion was lower (1.6% vs. 14.5%, p 5 0.02). Both groups had
comparable restenosis rates (26.5% vs. 26.9%, p 5 0.87).
Conclusions. This study demonstrates that combined antiplate-
let therapy after stent placement in patients with acute myocar-
dial infarction is associated with an overall better clinical and
angiographic outcome than anticoagulant therapy.
(J Am Coll Cardiol 1997;29:28–34)
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Primary angioplasty is an established intervention in acute
myocardial infarction (1–3). However, its success is compro-
mised by limitations, such as poor outcome in patients with an
unsuccessful procedure (4–6), a considerable incidence of
early reocclusion (7–9) and a high rate of late restenosis
(10,11). Intracoronary thrombus, dissections and residual ste-
nosis have been identified as risk factors for unfavorable
outcome after percutaneous transluminal coronary angioplasty
(PTCA) (12–14). Coronary stents may offer a solution because
they are able to tack up intimal flaps (15) and prevent vessel
closure after complicated PTCA (16,17); residual stenosis is
minimized by a greater immediate gain in lumen area, which is
in part responsible for a lower restenosis rate than after
balloon angioplasty (18,19). Stents may therefore be a suitable
device for improving reperfusion flow in the infarct-related
artery and to maintain better long-term patency. However,
concerns about the thrombogenicity of the metal surface of
stents adding to the thrombotic burden have discouraged their
use in acute myocardial infarction. These concerns were
enhanced by initial reports (16,20,21) in which rescue stenting
was associated with an increased risk for subsequent throm-
botic stent occlusion in vessels with an initial thrombus. For
this reason, reports describing a few successful cases of stenting
in acute myocardial infarction have advocated a more aggres-
sive anticoagulant regimen (22,23) or even intracoronary
thrombolytic agents after the procedure (22). In a recently
published study (24), we showed that stenting in acute myo-
cardial infarction is feasible and safe. Furthermore, these data
indicated that a post-stenting regimen with aspirin and ticlo-
pidine may be more effective than intense anticoagulation.
This finding was further supported by consecutive studies
reporting good results in acute myocardial infarction without
conventional anticoagulant therapy (25,26,39). Nevertheless, a
randomized trial on the effectiveness of different antithrom-
botic regimens after stent placement in the complicated setting
of acute myocardial infarction is lacking.
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The objectives of the present study were to analyze the
group of patients with stenting in acute myocardial infarction
in the Intracoronary Stenting and Antithrombotic Regimen
(ISAR) trial, a randomized comparison of combined antiplate-
let therapy (aspirin plus ticlopidine) with conventional antico-
agulant therapy (aspirin plus phenprocoumon with overlap-
ping intravenous heparin) after successful coronary stent
placement (27).
Methods
Patient selection. The ISAR trial was designed to assess
the effectiveness of two antithrombotic regimens after success-
ful coronary Palmaz-Schatz stent placement. Patients with
acute myocardial infarction within 48 h of the intervention
were included in the present analysis. The diagnosis of acute
myocardial infarction was based on typical chest pain lasting
.30 min accompanied by ST segment elevation $0.1 mV in
two or more adjacent leads on the electrocardiogram (ECG)
and an increase in creatine kinase (CK) concentration to twice
the upper limit of normal with a concomitant increase in the
CK MB isoenzyme. All patients with an acute myocardial
infarction admitted directly to our hospital underwent PTCA
as the primary treatment; 11 patients who had received throm-
bolytic therapy as the primary treatment at other hospitals
were also included the study because they were referred to us
for persistent or recurrent symptoms within the time frame set
by the study.
Extensive coronary artery dissection, complete vessel clo-
sure, residual diameter stenosis $30% after PTCA and lesions
in venous bypass grafts were indications for stenting. Success-
ful stent implantation (stent deployed at the desired position,
leaving a residual stenosis ,30%) and written informed con-
sent were the inclusion criteria for the trial. Patients were
considered ineligible if they had contraindications to the use of
aspirin, ticlopidine or phenprocoumon or absolute indications
for anticoagulant therapy. Furthermore, patients with cardio-
genic shock or mechanical ventilation, or both, before PTCA
were excluded.
Stent placement procedure. The protocol for stent implan-
tation at our institution has been previously described in detail
(17). Briefly, patients received intravenous heparin (15,000 U)
and aspirin (500 mg). Standard monorail balloon catheters
were used for angioplasty. After the criteria for stenting were
met, single-segment 7-mm or articulated 15-mm Palmaz-
Schatz stents (Johnson & Johnson) were crimped by hand onto
the angioplasty balloon. The balloons used for stent delivery
were chosen to be slightly oversized with respect to the target
vessel. In most patients, additional noncompliant balloon
catheters (High Energy, Boston Scientific, Hilden, Germany)
were used for final, high pressure stent dilation (mean maximal
balloon pressure 15.9 atm). One or more stents were im-
planted, depending on the length of the lesion or the associ-
ated dissection, or both. The choice of stent size, number of
stents and balloon was at the operators’ discretion. Intravas-
cular ultrasound examination was carried out in ,10% of
patients.
The arterial sheath was removed when the partial throm-
boplastin time (PTT) was ,60 s, usually within 3 h after the
intervention. Manual compression of the groin was performed
until local hemostasis was achieved, and a pressure bandage
was subsequently applied.
Antithrombotic regimen. After the pressure bandage was
applied, all patients received an intravenous heparin infusion
adjusted to maintain a PTT of 80 to 100 s. In patients assigned
to antiplatelet therapy, heparin infusion was stopped 12 h after
the stent placement procedure. Ticlopidine (250 mg twice
daily) (Tiklyd, Sanofi-Winthrop, Munich, Germany) was
started at the end of the procedure and continued for 4 weeks.
In patients assigned to anticoagulant therapy, phenprocou-
mon, a coumarin derivative (Marcumar, Hoffmann-La Roche,
Grenzach-Wyhlen, Germany) was initiated after stent place-
ment and given for 4 weeks. In this group of patients, heparin
was continued for an additional 5 to 10 days, until a stable level
of oral anticoagulation was achieved (target international
normalized ratio [INR] between 3.5 and 4.5). Both PTT and
INR were determined twice daily. Independent of the assigned
therapy, all patients were given aspirin (100 mg twice daily)
throughout the study. The concomitant cardiac medication was
left to the discretion of the attending physician.
Follow-up. Per protocol, all patients remained in the hos-
pital for at least 14 days to ensure 100% surveillance within this
early period. Enzyme determinations and ECG recordings
were obtained twice daily for the first 3 days and daily
afterward. Complete blood counts were performed three times
a week. Duplex ultrasound of the groin was carried out
routinely by operators unaware of the patient’s assigned ther-
apy. Coronary angiography was repeated whenever recurrent
myocardial ischemia was suspected. After discharge, patients
were seen in our outpatient clinic 1 month after the procedure.
Repeat angiography was scheduled at 6 months. All eligible
patients without angiographic follow-up were contacted at 6
months.
Angiographic assessment. Angiograms were assessed by
operators who had no knowledge of the assigned therapy for
Thrombolysis in Myocardial Infarction (TIMI) flow grade (28),
presence of dissection (29) or thrombus (30). Quantitative
analysis was applied to the preinterventional baseline angio-
gram, the maximally inflated balloon, the final post-stenting
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and follow-up angiograms. An edge detection algorithm
(AWOS, Siemens, Erlangen, Germany) was used for all mea-
surements, using the contrast-filled, nontapered catheter tip as
reference. Actual balloon diameter, coronary reference diam-
eter, minimal lumen diameter (MLD) and percent diameter
stenosis were obtained directly from this software. Elastic recoil
was defined as the difference between the diameter of the
maximally inflated balloon and the final, post-stenting MLD.
Acute gain was calculated as the difference between the final
and the baseline MLD and late loss as the difference between
final, post-stenting MLD and MLD at follow-up angiography.
Loss index was the calculated ratio of late loss to acute gain.
Restenosis was defined as a diameter stenosis $50% at repeat
angiography. Angiographic outcome at follow-up was assessed
in terms of restenosis rate, MLD and late lumen loss.
Definition of events. Clinical events were categorized as
cardiac and noncardiac events. Cardiac events were defined as
death of cardiac origin, myocardial infarction, aortocoronary
bypass surgery (CABG) or repeat PTCA of the stented vessel.
All deaths were considered cardiac unless a noncardiac etiol-
ogy had been established by autopsy. Diagnosis of recurrent
infarction was based on typical chest pain with new ECG
changes and an increase in creatine kinase. Cardiac events
were monitored throughout the follow-up period. Noncardiac
events were defined as death other than cardiac, cerebrovascu-
lar accident, severe peripheral vascular event or severe hem-
orrhagic event. A diagnosis of cerebrovascular accident was
made when a prolonged neurologic deficit was present. Severe
peripheral vascular events were pseudoaneurysms or arterio-
venous fistula at the access site requiring operation, and severe
hemorrhagic events were defined as bleeding complications
requiring operation or blood transfusions, or both (18).
Diagnosis of stent vessel occlusion was based on angio-
graphic TIMI flow grade 0 or 1. Repeat angiography was
performed for symptoms or as scheduled by the protocol.
Statistical analysis. Discrete variables were expressed as
counts and compared with the Fisher exact test. Continuous
variables were expressed as mean value 6 SD and compared
by means of unpaired, two-tailed t tests if normally distributed;
otherwise they were expressed using median and 2nd and 3rd
quartiles and statistically analyzed by means of the Mann-
Whitney U test. Because no patient was lost to follow-up, event
rates were analyzed with the Fisher exact test. The respective
relative risk, including the exact 95% confidence interval, was
computed for the group with antiplatelet therapy (31,32).
Event-free survival curves for all cardiac events and specifically
for recurrent myocardial infarction were obtained by the
Kaplan-Meier method. Statistical significance was assumed at
p , 0.05.
Results
During the study period, stent placement was attempted in
146 patients with acute myocardial infarction and was success-
ful in 123 who had been randomized for entry into the ISAR
trial (61 to antiplatelet therapy, 62 to anticoagulant therapy).
Sixteen patients were ineligible because of cardiogenic shock
or mechanical ventilation before PTCA, four because of
unsuccessful stent implantation, and three did not give con-
sent. In patients randomized, the indication for stent implan-
tation was abrupt closure in 4 patients, dissection in 90 and
residual stenosis in 29. Patients in the two therapeutic groups
did not differ significantly with respect to baseline clinical
(Tables 1 and 2) and angiographic variables (Table 3). Notably,
there was no difference in the frequency of risk factors for
atherosclerosis, extent of coronary artery disease, localization
and severity of acute myocardial infarction, TIMI flow grade
and time delay between the onset of symptoms and interven-
tion. There were 2.9 6 1.6 stent segments (7 mm)/vessel
implanted in the antiplatelet therapy group and 2.9 6 1.5 stent
segments/vessel in the anticoagulant group (p 5 0.87). All
patients had TIMI grade flow 3 at the end of the stent









Age (yr) 61.1 6 12.3 59.1 6 11.8 0.37
Women 16 (26.2) 14 (22.6) 0.86
Smoker 34 (55.7) 33 (53.2) 0.92
Hypercholesterolemia 14 (23.0) 17 (27.4) 0.72
Arterial hypertension 31 (50.8) 36 (58.0) 0.53
Diabetes mellitus 8 (13.1) 10 (16.1) 0.83
Multivessel disease 33 (54.1) 39 (62.9) 0.42
Previous CABG 0 (0) 2 (3.2) 0.50
Previous PTCA 4 (6.6) 3 (4.8) 0.98
Data are expressed as mean value 6 SD or number (%) of patients.
CABG 5 coronary artery bypass graft surgery; PTCA 5 percutaneous translu-
minal coronary angioplasty.









Time from onset of pain to intervention
,6 h 22 (36.7) 22 (35.5) 0.91
6–12 h 14 (23.0) 20 (32.3) 0.34
12–24 h 13 (21.7) 13 (21.0) 0.88
24–48 h 12 (20.0) 7 (11.2) 0.30
Q wave MI 49 (80.3) 54 (87.1) 0.44
Non-Q wave MI 12 (19.7) 8 (12.6) 0.44
Prior thrombolytic therapy 5 (8.2) 6 (9.7) 0.76
Localization of MI
Anterior 28 (45.9) 31 (50.0) 0.78
Lateral 5 (8.2) 6 (9.7) 0.98
Inferior 28 (45.9) 25 (40.3) 0.66
Killip class
I 51 (83.6) 51 (82.3) 0.97
II 7 (11.7) 7 (11.3) 0.83
III 3 (5.0) 4 (6.4) 0.98
Peak creatine kinase (U/liter) 1,0246 1,064 922 6 1,194 0.66
Data are expressed as mean value 6 SD or number (%) of patients. MI 5
myocardial infarction.
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placement procedure. A total of 25 patients received glyco-
protein (GP)IIb/IIIa inhibitors (abciximab c7E3, Reopro,
Beiersdorf-Lilly, Hamburg, Germany) for residual, angio-
graphically visible thrombus at the end of the procedure. Three
patients with anticoagulant therapy and abciximab had bleed-
ing complications; no other event occurred during subsequent
follow-up in these 25 patients.
Early outcome. Clinical events during the first 30 days are
summarized in Table 4. The incidence of all clinical events
(cardiac and noncardiac) within the first 4 weeks was signifi-
cantly lower in the antiplatelet than in the anticoagulant group
(3.3% vs. 21.0%, p 5 0.005).
Cardiac events. The combined cardiac event rate for car-
diac death, recurrent myocardial infarction, CABG or repeat
PTCA (whichever occurred first) was 1.6% in the antiplatelet
therapy group and 9.7% in the anticoagulant therapy group
(p 5 0.12), with a similar trend in the rate of myocardial
infarction (0% vs. 6.5%, p 5 0.12) and repeat intervention
(1.6% vs. 8.1%, p 5 0.21). With anticoagulant therapy, all
cardiac events were attributed to thrombotic stent vessel
occlusion. The single patient in the antiplatelet group with a
cardiac event required PTCA for recurrent symptoms resulting
from a nonocclusive distal lesion that had not been treated
during the initial stenting procedure; the stent site was widely
patent.
Stent vessel occlusion. There was a significantly lower rate
of stent vessel occlusion in patients with antiplatelet therapy
(0% vs. 9.7%, p 5 0.03). All six patients in the anticoagulant
group with this complication subsequently had an adverse
event: One died as a result of extensive myocardial infarction;
three had a nonfatal recurrent myocardial infarction; one had
a symptomatic and one an asymptomatic stent vessel occlusion;
all five surviving patients required either CABG (one patient)
or repeat PTCA (four patients). When these six patients were
compared with the group without stent vessel occlusion, there
was no significant difference in target vessel size (baseline
reference diameter 2.90 vs. 3.13 mm, p 5 0.34) and residual
stenosis after stent placement (2.6% vs. 1.7%, p5 0.88). Three
patients had a residual dissection after stent placement (vs.
16.7% in patients without stent vessel occlusion, p5 0.15). The
number of stent segments deployed was significantly higher in
patients with stent vessel occlusion (4.3 vs. 2.7, p 5 0.02). No
patient had angiographic evidence of a residual thrombus at
the end of the intervention; intravascular ultrasound was not
performed.
Noncardiac events. Antiplatelet therapy was associated
with a significantly lower risk of noncardiac events (1.6% vs.
12.9%, p 5 0.03). This was a result of a lower incidence of
hemorrhagic events (0% vs. 12.9%, p5 0.007) in the antiplate-
let therapy group. One patient in the antiplatelet group had an
ischemic stroke 2 h after the stent placement procedure, during
therapeutic heparin infusion.










LAD 28 (45.9) 27 (43.5) 0.94
LCx 6 (9.8) 9 (14.5) 0.61
RCA 27 (44.3) 25 (40.3) 0.80
Venous bypass graft 0 (0) 1 (1.6) 0.99
TIMI 0 or 1 flow 44 (72.1) 46 (74.2) 0.96
Restenotic lesion 6 (9.8) 5 (8.1) 0.98
Dissection before
stenting
43 (70.5) 47 (75.8) 0.65
Visible thrombus
before stenting
48 (78.7) 46 (74.2) 0.71
GPIIb/IIIa inhibitors
after stenting
12 (19.7) 13 (21.0) 0.96
Data are expressed as number (%) of patients. GP 5 glycoprotein; LAD 5
left anterior descending coronary artery; LCx 5 left circumflex coronary artery;
RCA 5 right coronary artery.








Value RR (95% CI)
Any clinical event 2 (3.3) 13 (21.0) 0.005 0.16 (0.02–0.65)
Cardiac event 1 (1.6) 6 (9.7) 0.12 0.17 (0–1.34)
Death or repeat MI 0 4 (6.5) 0.12 0 (0–1.10)
Death 0 1 (1.6) 0.99
MI 0 4 (6.5) 0.12 0 (0–1.10)
Repeat intervention 1 (1.6) 5 (8.1) 0.21 0.20 (0–1.70)
CABG 0 1 (1.6) 0.99
PTCA 1 (1.6) 4 (6.5) 0.37 0.25 (0–2.47)
Occlusion of stent vessel 0 6 (9.7) 0.03 0 (0–0.64)
Noncardiac event 1 (1.6) 8 (12.9) 0.03 0.13 (0–0.90)
Cerebrovascular accident 1 (1.6) 0 0.99
Hemorrhagic events 0 8 (12.9) 0.007 0 (0–0.45)
Peripheral vascular events 0 1 (1.6) 0.99
Data are expressed as number (%) of patients. CI 5 confidence interval; RR 5 relative risk; other abbreviations as
in Table 1.
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Late outcome. Cardiac events. The event-free survival
curve for all cardiac events (cardiac death, myocardial infarc-
tion, CABG and PTCA of the target vessel) is displayed in
Figure 1. The benefit of the antiplatelet therapy observed
during the first month after stenting was maintained through-
out the follow-up period. A total of 11 patients (18.0%) treated
with initial antiplatelet therapy and 15 (24.2%) with initial
anticoagulation had a cardiac event during this period (p 5
0.54). The majority of events after the first month were repeat
interventions: Eight patients in each group had repeat PTCA,
and two patients with antiplatelet therapy required CABG.
Two further cardiac deaths (both due to progressive heart
failure) occurred in the anticoagulant therapy group after the
first month, none with antiplatelet therapy. At 6 months, the
initial difference in the rate of death or recurrent myocardial
infarction became significant, with 9.7% in patients with initial
anticoagulant therapy versus 0% with antiplatelet therapy (p5
0.03). Survival free of recurrent myocardial infarction is illus-
trated in Figure 2. Not included in this analysis is one patient
in the anticoagulant therapy group who died of documented
bronchial carcinoma in the fourth month after stent placement.
Angiographic results. Six months after stent placement, 101
(86.3%) of the eligible patients had had follow-up angiogra-
phy. These data are illustrated in Table 5. There was no
significant difference between the two treatment groups in
either the restudy rate (83.1% vs. 90%, p 5 0.44) or the time
interval from stenting procedure (195 days, interquartile range
180 to 207 vs. 194 days, interquartile range 179 to 203, p 5
0.65). Angiography revealed three further stent vessel occlu-
sions with initial anticoagulant and one with initial antiplatelet
therapy. As illustrated in Figure 3, the cumulative rate of stent
vessel occlusion was 1.6% in the antiplatelet group and 14.5%
in the anticoagulant therapy group (p 5 0.02).
The quantitative angiographic analysis did not show any
significant difference in the baseline and post-stenting vari-
ables, including elastic recoil and acute lumen gain. At follow-
up, the mean minimal lumen diameter was 2.05 6 0.89 mm in
the antiplatelet and 1.89 6 0.90 mm in the anticoagulant
therapy group (Fig. 4). There were no significant differences in
diameter stenosis, late lumen loss and loss index. Thirteen
patients treated with initial antiplatelet and 14 with anticoag-
ulant therapy demonstrated restenosis at angiographic follow-
up, resulting in a restenosis rate of 26.5% for the antiplatelet
group and 26.9% for the anticoagulant therapy group (p 5
0.87).
Figure 1. Event-free survival curves for all cardiac events in both
treatment groups.
Figure 2. Survival curves free of recurrent myocardial infarction in
both treatment groups.
Figure 3. Cumulative rate of stent vessel reocclusion in both treatment
groups.










Reference diameter (mm) 3.22 6 0.61 3.03 6 0.55 0.10
Minimal lumen diameter (mm) 0.32 6 0.39 0.33 6 0.38 0.83
Diameter stenosis (%) 90.1 6 12.0 88.9 6 12.3 0.64
Immediately after stenting
Reference diameter (mm) 3.26 6 0.53 3.12 6 0.49 0.16
Minimal lumen diameter (mm) 3.12 6 0.45 3.05 6 0.45 0.42
Diameter stenosis (%) 3.3 6 10.7 1.2 6 12.9 0.37
At 6-mo follow-up
Reference diameter (mm) 3.21 6 0.55 3.05 6 0.49 0.11
Minimal lumen diameter (mm) 2.05 6 0.89 1.89 6 0.90 0.38
Diameter stenosis (%) 37.0 6 24.4 38.1 6 27.7 0.83
Balloon/vessel ratio 1.09 6 0.17 1.13 6 0.22 0.27
Elastic recoil (mm) 0.30 6 0.24 0.28 6 0.25 0.69
Acute lumen gain (mm) 2.81 6 0.51 2.72 6 0.54 0.40
Late lumen loss (mm) 1.08 6 0.86 1.16 6 0.76 0.60
Loss index 0.39 6 0.30 0.44 6 0.31 0.35
Restenosis rate (%) 26.5 26.9 0.87
Data are expressed as mean value 6 SD or as percent of target vessels.
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Discussion
Patients with acute myocardial infarction are at high risk for
complications during coronary interventions (33), in particular
patients with dissections or thrombi at the target lesion.
Despite the high risk profile of this subset of patients random-
ized in the ISAR trial, the present analysis demonstrates that
antiplatelet therapy may considerably improve the outcome
after stenting in acute myocardial infarction.
Reocclusion of stented vessel. Patency of the infarct-
related artery is a strong predictor of early and late outcome of
patients with acute myocardial infarction (10,33–36). However,
reocclusion after primary PTCA in acute myocardial infarction
has been observed in 10% to 25% of patients (7,8). In earlier
reports (23) of stenting in acute myocardial infarction, the
reocclusion rate with initial anticoagulant therapy was ;10%.
The main finding of the present study is a significant reduction
in the incidence of stent vessel occlusion by antiplatelet
therapy: The cumulative reocclusion rate was 1.6% for anti-
platelet therapy compared with 14.5% for anticoagulant ther-
apy (Fig. 3).
When patients with stent vessel occlusion were compared
with those without such an event, the number of stent segments
deployed was significantly higher; other procedural and angio-
graphic variables were not significantly different. This finding
might suggest that patients with procedures in longer lesions
have a higher risk for subsequent stent vessel occlusion if they
receive anticoagulant therapy. However, sample sizes in the
present study were too small to allow comprehensive analysis
of the risk for stent vessel occlusion.
Clinical outcome. Antiplatelet therapy was associated with
a significantly lower rate of noncardiac events (1.6% vs.
12.9%), a trend for fewer cardiac events (1.6% vs. 9.7%) and a
higher rate free of myocardial infarction than anticoagulant
therapy. In a recent preliminary report from the French
Registry of Stenting in Acute Myocardial Infarction (26),
significantly higher cardiac mortality and nonfatal myocardial
infarction rates were observed in the anticoagulant group than
in the antiplatelet group. Comparison of these data with our
results is limited because inclusion criteria and clinical charac-
teristics were not reported, and a slightly different antithrom-
botic regimen, including low molecular weight heparin in
addition to aspirin and ticlopidine was used after stenting.
Angiographic restenosis. Angiographic follow-up did not
reveal a significant difference between the two treatment
groups with respect to restenosis rate and other angiographic
indexes of restenosis, despite the favorable influence of anti-
platelet therapy on the incidence of thrombotic stent occlu-
sions. Saito et al. (37) recently reported a 17% restenosis rate
in patients with stenting for acute myocardial infarction treated
without Coumadin. However, these data were obtained in
selected patients with target vessels$2.5 mm in diameter, with
an angiographic follow-up rate of 65%. Violaris et al. (38)
recently found that angiographic evidence of thrombus before
PTCA was associated with a higher incidence of vessel occlu-
sion during follow-up. However, when totally occluded vessels
were excluded from this analysis, the restenosis rate was similar
to that in patients without thrombus. The results of the present
study comparing two different antithrombotic regimens are
concordant with observations in previous studies, where nu-
merous pharmacologic efforts were ineffective in reducing the
restenosis rate (39).
Restenosis occurred at 6 months in;27% of patients in our
study, whereas in other studies it was observed in almost 50%
after primary PTCA for acute myocardial infarction (10,11,37).
These angiographic data suggest that stenting in acute myo-
cardial infarction may result in a markedly lower long-term
restenosis rate than primary PTCA.
Limitations of the study. In this study we analyzed a subset
of the ISAR trial—patients with stent placement for acute
myocardial infarction. The two groups constituted a relatively
small series, and the number of patients with adverse events
was low. These factors have to be considered in interpreting
our data.
The target INR of 3.5 to 4.5 with anticoagulant therapy in
the ISAR trial was higher than that currently used or recom-
mended and relatively high compared with other studies
(18,19). Although the rate of bleeding complications compares
well with previous reports (i.e., Belgian Netherlands Stent
study [BENESTENT] [19], 13.5%), a lower target INR might
have resulted in a lower rate of bleeding complications.
Some comparisons in the present study were made with
historical data for PTCA in patients with acute myocardial
infarction. However, randomized studies comparing primary
PTCA with stent placement in acute myocardial infarction are
necessary for a reliable assessment of the best management
strategy. In providing favorable data with regard to antiplatelet
therapy, this study may help to determine the most appropriate
post-stenting treatment in future randomized trials.
Conclusions. This study demonstrates that the outcome
after coronary stent placement in patients with acute myocar-
dial infarction is improved by combined antiplatelet therapy
compared with conventional anticoagulant therapy. The major
benefits achieved were a significant lowering of the rate of
Figure 4. Cumulative distribution curves for minimal lumen diameter
before (Pre), immediately after stenting (Post) and at angiographic
follow-up for both treatment groups.
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stent vessel occlusion and an improvement in late survival
without recurrent myocardial infarction. In addition, antiplate-
let therapy was associated with a lower incidence of hemor-
rhagic complications.
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